|
Variable
|
OS
|
RFS
|
|---|
|
n
|
HR (95% CI)
|
P-valuea
|
I2
|
P-valueb
|
n
|
HR (95% CI)
|
P-valuea
|
I2
|
P-valueb
|
|---|
|
Yearc
|
|
> Median
|
2
|
2.93 (1.62,5.31)
|
<0.001
|
0%
|
0.7
|
1
|
4.04 (1.86,8.78)
|
<0.001
|
–
|
–
|
|
≤ Median
|
6
|
2.78 (1.79,4.30)
|
<0.001
|
0%
|
43%
|
2
|
5.48 (2.54,11.79)
|
<0.001
|
0%
|
0.59
|
|
Country
|
|
East Asia
|
4
|
3.34 (1.58,7.09)
|
0.002
|
12%
|
0.33
|
0
|
–
|
–
|
–
|
–
|
|
non-East Asia
|
4
|
2.68 (1.76,4.08)
|
<0.001
|
0%
|
0.69
|
3
|
4.71 (2.73,8.13)
|
<0.001
|
0%
|
0.75
|
|
Patient no.d
|
|
>Median
|
4
|
2.89 (1.93,4.31)
|
<0.001
|
0%
|
0.96
|
1
|
5.06 (2.23,11.48)
|
<0.001
|
–
|
–
|
|
≤ Median
|
4
|
2.89 (1.03,8.13)
|
0.04
|
37%
|
0.19
|
2
|
4.45 (2.15,9.24)
|
<0.001
|
0%
|
0.47
|
|
Sampling time
|
|
Baseline
|
7
|
2.85 (2.00,4.07)
|
<0.001
|
0%
|
0.54
|
3
|
4.71 (2.73,8.13)
|
<0.001
|
0%
|
0.75
|
|
intra-therapy
|
1
|
2.04 (0.18,23.12)
|
0.56
|
–
|
–
|
0
|
–
|
–
|
–
|
–
|
|
Cutoff value
|
|
≥ 1/7.5 ml
|
4
|
2.89 (1.93,4.31)
|
<0.001
|
0%
|
0.96
|
3
|
4.71 (2.73,8.13)
|
<0.001
|
0%
|
0.75
|
|
≥ 2/7.5 ml
|
4
|
2.89 (1.03,8.13)
|
0.04
|
37%
|
0.19
|
0
|
–
|
–
|
–
|
–
|
|
Positive ratee
|
|
>Median
|
4
|
2.09 (1.17,3.74)
|
0.01
|
0%
|
0.91
|
1
|
4.04 (1.86,8.78)
|
<0.001
|
–
|
–
|
|
≤ Median
|
4
|
3.38 (2.17,5.26)
|
<0.001
|
0%
|
0.41
|
2
|
5.48 (2.54,11.79)
|
<0.001
|
0%
|
0.59
|
|
Quality
|
|
High
|
7
|
2.61 (1.82,3.75)
|
<0.001
|
0%
|
0.95
|
3
|
4.71 (2.73,8.13)
|
<0.001
|
0%
|
0.75
|
|
Low
|
1
|
11.12 (2.51,49.26)
|
–
|
–
|
0.17
|
0
|
–
|
–
|
–
|
–
|
|
Overall
|
8
|
2.83 (1.99,4.03)
|
<0.001
|
0%
|
0.65
|
3
|
4.71 (2.73,8.13)
|
<0.001
|
0%
|
0.75
|
- aP-value for estimates of HR.
- bP-value for heterogeneity
- c The median year of Os and PFs was 2015 and 2018, respectively
- d The median patient number of Os and PFs was 41.5 and 76, respectively
- e The median positive rate of Os and PFs was 23.8 and 18%, respectively
- “-”: not available
